Valneva SE (NASDAQ:VALN - Get Free Report) shares traded up 6.2% during mid-day trading on Monday . The company traded as high as $6.16 and last traded at $6.35. 13,553 shares were traded during trading, a decline of 49% from the average session volume of 26,764 shares. The stock had previously closed at $5.98.
Wall Street Analysts Forecast Growth
Several analysts have recently commented on the stock. HC Wainwright reiterated a "buy" rating and issued a $17.00 target price on shares of Valneva in a report on Wednesday. Guggenheim decreased their price objective on shares of Valneva from $17.00 to $15.00 and set a "buy" rating for the company in a research note on Monday, March 24th.
Get Our Latest Stock Report on Valneva
Valneva Price Performance
The stock has a market cap of $511.13 million, a P/E ratio of -48.38 and a beta of 1.85. The business has a 50 day simple moving average of $6.98 and a 200-day simple moving average of $5.63. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78.
Valneva (NASDAQ:VALN - Get Free Report) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.32). Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%. The company had revenue of $56.48 million for the quarter, compared to analysts' expectations of $55.64 million. On average, sell-side analysts forecast that Valneva SE will post 0.13 EPS for the current year.
Hedge Funds Weigh In On Valneva
Several institutional investors and hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC bought a new position in shares of Valneva during the 1st quarter worth $94,000. ABC Arbitrage SA bought a new position in Valneva during the fourth quarter worth about $84,000. Finally, Wells Fargo & Company MN increased its stake in shares of Valneva by 14.3% in the fourth quarter. Wells Fargo & Company MN now owns 246,766 shares of the company's stock worth $1,079,000 after purchasing an additional 30,859 shares in the last quarter. 11.39% of the stock is owned by institutional investors.
Valneva Company Profile
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
Recommended Stories
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
